A combination regimen based on #Pfizer's BRAF inhibitor #Braftovi achieved a 51% reduction in the risk of death in patients when used first-line to treat patients with a form of #colorectalcancer, putting it odds-on for a full FDA approval.

pharmaphorum.com/news/asco-25...

Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting | Pfizer More than 60 abstracts, including 15 oral and rapid oral presentations, highlight advancements across Pfizer’s industry-leading Oncology portfolio ASCO press program to feature overall survival and pr...

Pfizer unveils its bold vision for the future of cancer care at #ASCO25 — with over 60 abstracts spotlighting breakthroughs in colorectal, breast & thoracic cancers. Big moves in #Oncology.
#CancerResearch #TCSC #Pfizer #BRAFTOVI #ADC #VERITAC2 #ColorectalCancer

www.pfizer.com/news/press-r...

Pfizer drug acquired in $11B buyout confirms benefit in colon cancer The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval — boosting an oncology portfolio Pfizer is looking to for revenue growth.

Pfizer drug acquired in $11B buyout confirms benefit in colon cancer #BRaf #Encorafenib #braftovi www.biopharmadive.com/news/pfizer-...

Maria (Masha) Babak: FDA grants accelerated approval to Braftovi for the treatment of metastatic colorectal cancer - OncoDaily Maria (Masha) Babak: FDA grants accelerated approval to Braftovi for the treatment of metastatic colorectal cancer / Braftovi, cancer, cetuximab, colorectal

FDA grants accelerated approval to Braftovi for the treatment of metastatic colorectal cancer - Maria (Masha) Babak
@thebabaklab.bsky.social
@fda.gov

oncodaily.com/blog/222646

#Braftovi #Cancer #Cetuximab #ColorectalCancer #FDA #Encorafenib #mCRC #mFOLFOX6 #OncoDaily #Oncology #Medicine #Health

Weekly Roundup - PHARMA - 6 January 2025 🔊BMS's Opdivo Qvantig FDA-Approved for Subcutaneous Use in NSCLC and Solid Tumors Bristol Myers Squibb's Opdivo Qvantig receives FDA approval for subcutaneous use in NSCLC and other solid tumors. The ...

Weekly Roundup - PHARMA - 6 January 2025

www.linkedin.com/pulse/weekly...

kstrategyand.com/pharma-news

#FDA #Hikma #GLP1 #Victoza #EliLilly #Zepbound #ObesityTreatment #RhythmPharma #Setmelanotide #Imcivree #GeneticObesity #Pfizer #Braftovi #Humanteconomy #Humantec #KStrategyand